Literature DB >> 20730470

Posterior reversible encephalopathy syndrome in a patient with hepatitis B induced type 1 membranoproliferative glomerulonephritis.

Vishwanath Sathyanarayanan1, Abdul Razak, Girish Narayan, Mukhyaprana Prabhu, Balasubramanian Ramachandran, Kudva Ranjini, Monappa Vidya, Kusum Joshi.   

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a rare complication of nephrotic syndrome and corticosteroid therapy. Here, we discuss an 18 year old man with type 1 membranoproliferative glomerulonephritis (MPGN) secondary to hepatitis B infection who developed posterior leukoencephalopathy while on therapy with lamivudine and prednisone. He developed seizures and vision loss. He also had hypertension, but no sudden elevation was recorded at any time. Magnetic resonance imaging revealed patchy areas of altered signal intensity involving cortical gray and subcortical white matter in the bilateral frontoparietal regions, occipital cortices, temporal cortices and cerebellar hemispheres, and hyperintensity on T2W and FLAIR sequences. Tapering of prednisone and controlling hypertension resulted in clinical improvement within a few days, and in a month MRI was normal. Diagnosing PRES requires a high index of suspicion when treating similarly susceptible patients. PRES as a complication during the treatment of MPGN secondary to hepatitis B has, to our knowledge, never been reported previously in the literature.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20730470     DOI: 10.1007/s10157-010-0331-y

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  16 in total

1.  Posterior leukoencephalopathy syndrome during steroid therapy in a down syndrome patient with nephrotic syndrome.

Authors:  B S Kim; S H Lee; J E Lee; S W Chung; Y O Kim; K B Choi; E J Choi; B K Bang
Journal:  Nephron       Date:  2001-03       Impact factor: 2.847

2.  Hypertensive encephalopathy and nephrotic syndrome: a possible link?

Authors:  E R Pearson; R J D'Souza; C Hamilton-Wood; A J Nicholls; M Beaman
Journal:  Nephrol Dial Transplant       Date:  1999-07       Impact factor: 5.992

3.  Reversible posterior leukoencephalopathy syndrome: a report of 2 cases.

Authors:  A Arora; D Chowdhury; M K Daga; N Arora; M Gaiha
Journal:  Neurol India       Date:  2001-09       Impact factor: 2.117

4.  HBV associated nephrotic syndrome: resolution with oral lamivudine.

Authors:  F L Connor; A R Rosenberg; S E Kennedy; T D Bohane
Journal:  Arch Dis Child       Date:  2003-05       Impact factor: 3.791

5.  Reversible posterior leukoencephalopathy associated with minimal change nephrotic syndrome.

Authors:  Jen Li Looi; Jonathan P Christiansen
Journal:  N Z Med J       Date:  2006-10-13

Review 6.  Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis.

Authors:  F Fabrizi; V Dixit; P Martin
Journal:  Aliment Pharmacol Ther       Date:  2006-09-01       Impact factor: 8.171

7.  Successful treatment of hepatitis B virus (HBV)-associated membranoproliferative glomerulonephritis (MPGN) with alpha interferon.

Authors:  N A Abbas; M A Pitt; A T Green; L R Solomon
Journal:  Nephrol Dial Transplant       Date:  1999-05       Impact factor: 5.992

8.  The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia.

Authors:  K N Lai; J S Tam; H J Lin; F M Lai
Journal:  Nephron       Date:  1990       Impact factor: 2.847

9.  Complete remission of nephrotic syndrome of hepatitis B virus-associated membranous glomerulopathy after lamivudine monotherapy.

Authors:  Tang-Wei Chuang; Chao-Hung Hung; Shun-Chen Huang; Chuan-Mo Lee
Journal:  J Formos Med Assoc       Date:  2007-10       Impact factor: 3.282

10.  Acute posterior leukoencephalopathy in a patient with nephrotic syndrome.

Authors:  Kouichi Utsumi; Shimon Amemiya; Miho Iizuka; Yasuhiko Iino; Yasuo Katayama
Journal:  Clin Exp Nephrol       Date:  2003-03       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.